What's Happening?
Pittsburgh-based insurer Highmark is expanding its drug offerings through CivicaScript, focusing on biosimilars to combat rising pharmaceutical costs. Highmark, a founding member of CivicaScript, aims
to provide lower-cost alternatives to expensive generic drugs. The insurer initially introduced abiraterone acetate, a prostate cancer treatment, through CivicaScript in 2023, resulting in significant savings for members. As of September 2025, Highmark has added four more CivicaScript products: dimethyl fumarate and dalfampridine for multiple sclerosis, droxidopa for neurogenic orthostatic hypotension, and capecitabine, a cancer drug. Corey DeLuca, Highmark's vice president of clinical and specialty pharmacy services, noted that these efforts have reduced costs for both plan sponsors and patients. Highmark is also working to increase access to biosimilars, partnering with Free Market Health to match specialty medication referrals with pharmacies based on cost and value.
Why It's Important?
This expansion is significant as it addresses the ongoing issue of high drug prices in the U.S., which affects both patients and healthcare providers. By offering more affordable alternatives through CivicaScript, Highmark is helping to alleviate the financial burden on patients who require expensive medications. The introduction of biosimilars, which are typically less costly than branded drugs, could lead to broader access to necessary treatments, improving patient adherence and outcomes. This initiative aligns with broader healthcare industry trends towards cost reduction and increased accessibility, potentially setting a precedent for other insurers to follow.
What's Next?
Highmark plans to continue expanding its drug offerings and partnerships to further reduce costs and improve access to medications. The insurer is actively exploring ways to collaborate with retail pharmacies to enhance drug availability. As more biosimilars enter the market, Highmark will likely focus on integrating these options into their formularies, working closely with healthcare providers to ensure a smooth transition for patients. The success of these initiatives could prompt other insurers to adopt similar strategies, potentially leading to widespread changes in how medications are priced and accessed in the U.S.
